New reviews and commentaries, 2 April 2012

2 April 2012

Can genomics bend the cost curve?
 
Broadening research consent in the era of genome-informed medicine.
 
Debunking the myth that whole-genome sequencing infringes thousands of gene patents.
 
The human microbiome: at the interface of health and disease.
 
Tumor heterogeneity and personalized medicine.
 
Incidental benefits.
 
Genetics: broken giant linked to heart failure.
 
Chipping away at the lung cancer genome.
 
Genomics contest underscores challenges of personalized medicine.
 
Monogenic mitochondrial disorders.
 
Transformative mutation specific pharmacotherapy for cystic fibrosis.
 
Stem cell based therapy - where are we going?
 
Biobanking: shifting the analogy from consent to surrogacy.
 
What makes UK Biobank special?
 
New "first families": the psychosocial impact of new genetic technologies.

More from us